



Mark Lebwohl, MD
Professor and Chairman
Department of Dermatology

Mount Sinai School of Medicine
5 East 98th Street, 5th Floor
Box 1048
New York, NY 10029-6574

3384 6 Tel: (212)-241-9728 243
Fax: (212)-876-5661

December 11, 2006

Food and Drug Administration
ATTN: Division of Dockets Management
5630 Fishers Lane, Room 1061, HFA-301
Rockville, MD 20852

RE: Docket #1978N-0065, RIN 0910-AF53

Dear Sirs:

I am writing to strongly object to the possibility that you may remove one of the most effective treatments we have for the treatment of pigmentary disorders. Hydroquinones have been available for decades. I am not aware of there ever having been a single serious adverse event to hydroquinones. They are useful for post-inflammatory pigmentary change, melasma, lentiginos, and other pigmentary disorders. If this highly useful therapy is taken away from us, it will undoubtedly be replaced by other treatments that have more side effects. Moreover, the conditions for which hydroquinone is useful are often psychologically devastating, so that the benefits of this treatment far outweigh the unrealistic remote possibilities of side effects.

Sincerely,

Mark Lebwohl, M.D.

ML:mr

78N-0065

C 67